Keith Loria

A team of Researchers developed a "recovery index" that integrates three factors related to the six-minute walk test.

Stereotactic ablative radiotherapy, also referred to as stereotactic body radiation therapy, has emerged as a standard noninvasive treatment alternative, offering high local control rates with relatively limited toxicity in carefully selected patients.

Because familial idiopathic pulmonary fibrosis is associated with earlier onset and worse outcomes, there are questions about the effectiveness of the antifibrotics as a treatment.

Several lines of evidence suggest that testing the traditional drug for diabetes might benefit people with idiopathic pulmonary fibrosis.

The findings challenge the conventional view that daytime sleepiness is always a result of insufficient sleep, poor sleep hygiene or classic sleep disorders.

Researchers used nanoparticle technology to encapsulate paclitaxel and target bladder tumors more effectively. Early results demonstrate tumor elimination and minimal side effects.

The new radiotracer takes advantage of two biological targets linked to fibrotic and inflammatory processes in the lung: fibroblast activation protein and integrin receptors.

Researchers found that participants with excessive daytime sleepiness had significantly lower maximum tongue pressure, poorer chewing performance and diminished swallowing function.

New study shows catheter ablation significantly was associated with a 40% drop in major cardiovascular events and a 70% decline in all-cause mortality for patients with both atrial fibrillation and obstructive sleep apnea.

Given the long latency and broad spectrum of respiratory conditions associated with military deployment, the findings underscore the need for long-term medical surveillance and specialized respiratory care for veterans.

The AI-powered imaging technology quantifies the extent of fibrosis on CT scans and also measures other features, such as ground-glass opacification.

Early-stage research suggests a strategy for suppressing bladder cancer growth at the RNA level.

New technology generates “nanotube highways” between cancer cells, enabling better drug penetration and tumor-killing effectiveness while minimizing harm to surrounding healthy tissue in animal studies of bladder cancer.

Kates, a nationally recognized expert on bladder cancer, lends credibility to the company’s efforts to develop a new treatment for bladder cancer.

Researchers used a data textural analysis to quantify changes seen on high-resolution CT scans.

An off-target interaction with nuclear receptor PPARγ may trigger a sequence of events that results in lung injury.

The results of the FIBRONEER trial were the basis for the FDA approval of nerandomilast in October 2025.

Researchers in China combined findings from MRI scans with clinical features to create a new predictive model for nonmuscle-invasive bladder cancer recurrence.

The PIVOT-006 trial is part of a larger national effort to evaluate cretostimogene’s safety and effectiveness in bladder cancer.

The differing regulation of key fibrotic pathways suggest that idiopathic pulmonary fibrosis involves dysregulation rather than just a speeded-up aging process.

Site neutrality payment, innovations in care delivery and value-based pricing of drugs could at least help to moderate the huge growth in expenditures.

The FDA approved the system in September 2025.